IntelliGenome Partners with Cornell University to Develop Portable TB Diagnostic Solution
IntelliGenome, a leader in CRISPR-based in vitro diagnostic technology, has announced a research and development subaward agreement with Cornell University. This collaboration aims to develop a rapid, low-cost, and portable diagnostic solution for tuberculosis (TB). The project is part of a National Institutes of Health (NIH)-funded program focused on enhancing access to innovative health technologies. The initiative will utilize IntelliGenome's point-of-care testing (POCT) platform to detect cell-free DNA from Mycobacterium tuberculosis in both respiratory and blood samples. This approach seeks to address the limitations of current TB diagnostic methods, which often rely on sputum samples and centralized laboratory workflows, potentially delaying treatment. The new solution integrates sample processing with CRISPR-based detection, aiming to provide faster and more accessible testing, especially in areas with limited laboratory infrastructure. 
